Catalog Advanced Search

Search by Category
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Contains 5 Component(s)

    The ASTCT and WBMT webinar, Allogeneic Stem Cell Transplantation for Non-malignant Disorders: a Global Perspective, was presented on November 24th, 2021 from 6 AM - 7:30 AM CST.

    This webinar was organized by the Worldwide Network for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy. The webinar provides an overview of the current knowledge and best practices for allogeneic stem cell transplantation (HCT) in patients with non-malignant disorders (NMD). 

    Program and Speakers: 

    - Welcome and Introduction: Yoshihisa Kodera and Domiano Rondelli


    - The Global State of HCT for NMD: Results of the WBMT Survey

                    Dietger Niederwieser - University of Leipzig, Germany


    - What should we consider about the donor when performing HCT in NMD?

                    Nina Worel - Medical University of Vienna, Austria

     


    - HCT in Bone marrow failure syndromes: severe aplastic anemia-Fanconi anemia

                    Nada Hamad - St Vincent´s Hospital, Sydney, Australia

     


    - HCT in Thalassemia

                    Vikram Mathews - Christian Medical College, Vellore, India

     


    - HCT in sickle cell disease

                    Selim Corbacioglu - University of Regensburg, Germany

     


    - HCT for primary immunodeficiencies

                    Carmem Bonfim - Hospital Pequeno Principe, Curitiba, Brazil


    - Panel discussion: “Sharing experiences from different world regions” 

  • Contains 1 Component(s)

    The Pharmacy SIG Online Journal Club session will be presented on November 10th, 2021 at 2 pm CT/3 pm ET.

    Presenters & Articles

    Lindsey Catlin, PharmD
    PGY2 Oncology Resident
    St Luke's Health System
    Autologous Transplant versus Chimeric Antigen Receptor T-cell Therapy for Relapsed DLBCL in Partial Remission

    Jack Malespini, PharmD
    PGY2 Oncology Pharmacy Resident
    Massachusetts General Hospital
    jmalespini@mgh.harvard.edu 
    Post-transplant Cyclophosphamide Versus Thymoglobulin in HLA Mismatched Unrelated Donor Transplant for Acute Myelogenous Leukemia and Myelodysplastic Syndrome

     

    Session Learning Objectives:

    Upon completion of the activity, participants should be able to:

    - Discuss recent BMT pharmacy studies and their applications to current practice.
    - Evaluate the role of autologous transplant versus treatment with chimeric antigen receptor t-cell therapy in patients with relapsed DLBCL in partial remission.
    - Compare and contrast the utility of post-transplant cyclophosphamide (PTcy) versus thymoglobulin for graft versus host disease (GVHD) prophylaxis in mismatched unrelated donor (MMUD) transplantation.

    This activity is jointly provided by The France Foundation and ASTCT. The France Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education and will award 1.0 CEU to pharmacists who complete the activity, complete the registration and evaluation forms, and successfully pass a post-test (>75%).

    Full CE information, including presenter disclosures and accreditation information, can be found in the Handouts tab or directly downloaded by clicking here.

  • Contains 1 Component(s)

    The Pharmacy HCT Core Topics Live Session will be presented on November 3rd, 2021 at 2:30 pm CT / 3:30 pm ET.

    ASTCT Pharmacy HCT Core Topics Connection - Live

    This interactive live session will give learners the opportunity to talk with the Pharmacy SIG HCT Core Topics Connection presenters live. Participants will rotate to each topic for a follow-up discussion on each of the four modules.

    Speakers and Topics:

    - Graft-versus-Host Disease (GVHD) – Presented by Zahra Mahmoudjafari, PharmD, BCOP, DPLA and Rebecca Gonzalez, PharmD, BCOP

    - Infection Prophylaxis in HCT – Presented by Arpita Shah Gandhi, PharmD, BCOP and Dennis Marjoncu, PharmD, BCOP

    - Chimeric Antigen Receptor (CAR) T-cell Therapies – Presented by Katie S. Gatwood, PharmD, BCOP and May T. Aziz, PharmD, BCOP

    - Conditioning Regimens Used in Hematopoietic Cell Transplantation – Presented by Binni Kunvarjee, PharmD, BCOP, Maggie Nelson, PharmD, BCOP, and Vinita Pai, PharmD, MS

  • Contains 2 Component(s)

    This webinar aired live on October 28, 2021, as the fifth installment of the CAR T Webinar Series from ASTCT. This webinar featured presentations highlighting the key areas of logistics for operating CAR T programs, including reimbursement structure, inpatient vs. outpatient settings, programs in developing countries, data management, and clinical trials. There was also a robust panel discussion on these topics moderated by Dr. Antonio Macedo.

    This webinar aired live on October 28, 2021, as the fifth installment of the CAR T Webinar Series from ASTCT. This webinar featured presentations from Dr. Renato Cunha, Dr. Katie Gatwood, and Dr. Zahra Mahmoudjafari highlighting the key areas of logistics for operating CAR T programs, including reimbursement structure, inpatient vs. outpatient settings, programs in developing countries, data management, and clinical trials. There was also a robust panel discussion on these topics moderated by Dr. Antonio Macedo.


    Speakers:

    Dr. Katie Gatwood is a board-certified oncology pharmacist practicing as a Clinical Pharmacist Specialist in Adult Stem Cell Transplant and Cellular Therapy at Vanderbilt University Medical Center in Nashville, TN. She is passionate about clinical research and education, and has authored several publications and textbook chapters related to management of cellular therapy patients, including chimeric antigen receptor T-cell therapy. She is an active member of the American Society for Transplantation and Cellular Therapy (ASTCT) and was the recipient of the 2021 ASTCT Pharmacy SIG New Practitioner Award.

    Dr. Zahra Mahmoudjafari is a board certified oncology pharmacist. She earned her doctorate of pharmacy at the University of Missouri-Kansas City and completed her pharmacy practice residency at The Ohio State University Medical Center in Columbus, Ohio and her oncology specialty residency the Huntsman Cancer Institute in Salt Lake City, Utah. She currently works as a Clinical Pharmacy Manager for Hematology/Blood and Marrow Transplant and Cellular Therapeutics at the University of Kansas Health System. She also currently serves as the residency program director for the PGY2 Oncology residency program. She maintains active organizational involvement with the Hematology Oncology Pharmacists Association (HOPA), Advanced Topics for Oncology Pharmacy Professionals (ATOPP) as well as the American Society for Transplantation and Cellular Therapeutics (ASTCT) where she had served as chair of the Pharmacy Special Interest Group and participates in committees such as the Practice Guidelines Committee, Government Relations Committee and Content Committee.

    Dr. Renato Cunha graduated in Medicine from the Faculty of Medicine of the Federal University of Uberlândia, and was a Clinical Fellow in Hematology (2009), and Bone Marrow Transplantation and Cell Therapy (2010) at the Clinical Hospital of Ribeirão Preto Medical School of University of São Paulo. Postdoctoral Fellowship in Bone Marrow Transplantation and Cell Therapy at the National Cancer Institute (ETIBNCI/NHI) in Bethesda, USA (2015-2018). Member of the Brazilian Society of Bone Marrow Transplant, the American College Physician, the American Society of Hematology, and the American Society for Transplantation and Cellular Therapy. Currently, Assistant Professor of Medicine and Head of the Bone Marrow Transplantation and Cell Therapy Unit at the Clinical Hospital of Ribeirão Preto Medical School of the University of São Paulo (BMTU-HCFMRPUSP). In 2018 was awarded the ASH Global Research Award and in 2019, performed the first car t-cell treatment in Latin America in Ribeirão Preto, Brazil. In 2021, coordinate the first Brazilian Consensus of Advanced Cellular Therapy of the Brazilian Association of Hematology, Hemotherapy and Cellular Therapy.

  • Contains 4 Component(s)

    The ASTCT October Journal Club session aired live on October 27th, 2021.

    ASTCT October Journal Club Session – Aired Live on October 27th, 2021

    The American Society for Transplantation and Cellular Therapy (ASTCT) Committee on Education is expanding the Journal Club initiative that was started by the ASTCT Pharmacy SIG to keep the hematopoietic cell transplantation and immunotherapy community engaged with new and enriching literature. This webinar consisted of two, 30-minute journal club presentations, which included 20 min for presentation and 10 min for discussion/Q and A.

    Presenters & Articles

    Amanda Lipsitt, BMTCT Fellow at St. Jude Children's Research Hospital

    Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease 

    Abdul Moiz Khan, PGY4 Fellow Hematology/Oncology at Karmanos Cancer Institute

    Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study


  • Contains 4 Component(s), Includes Credits

    Join us on September 29 at 12 PM CT, for the fourth and final webinar in the new ASTCT & NMDP Sickle Cell Webinar Series, in honor of Sickle Cell Awareness month. This webinar will feature presentations from clinicians and patient speakers on guidelines for post-transplant care and updated CIBMTR outcomes data.

    Join us on September 29 at 12 PM CT, for the fourth and final webinar in the new ASTCT & NMDP Sickle Cell Webinar Series, in honor of Sickle Cell Awareness month. This webinar will feature presentations from clinicians and patient speakers on guidelines for post-transplant care and updated CIBMTR outcomes data. Other topics include:

    - Expectations for organ function and recovery
    - Ongoing psychosocial supports for patients and their families
    - Updated outcomes data from CIBMTR, including: overall survival and subsequent cancers after transplant

    This webinar will be moderated by Dr. Rachel Phelan, and feature presentations by Dr. Mary Eapen from the Medical College of Wisconsin, and Dr. Elizabeth Stenger from UPMC Children's Hospital of Pittsburgh. Each webinar in this series will also highlight patient's lived experiences within each of the topics.

    There will be a short Q&A section at the end of the webinar, so be sure to register and submit any questions in advance that you would like answered during the webinar by emailing info@astct.org. This webinar will be recorded and the recording and slides will be posted 24-48 hours after the live event.

    Accreditation Statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and the American Society for Transplantation and Cellular Therapy (ASTCT). The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.

    Continuing Medical Education Information

    This activity is jointly provided by The France Foundation and the American Society for Transplantation and Cellular Therapy.                

    Statement of Need:

    The Sickle Cell Warriors Program at NMDP is a patient services program that assists in typing for patients, financial assistance, counseling, patient education and providing peer connections. The primary feedback from patients in the Sickle Cell Warrior Program is that #1 barrier to treatment is physicians. Patients report that they are not being told about all of their treatment options; regardless of disease severity, they should at least be made aware of various options, but often they are not. Many patients go to the Sickle Cell Warriors Program to enroll in a clinical trial for transplant, but this usually does not cover cost of HLA typing. In this case, the referring physician has not gone through the process of HLA typing, either because of misinformation or because the physician refuses to provide an order for typing simply because they don’t agree with patients physicians. This is a clear miscommunication between the community oncologists and transplant physicians. In surveys, transplant physicians identify a lack of awareness, lack of confidence, and reliance on outdated data from the referring physicians. These referring physicians in a similar survey reported that their primary reason for not communicating all treatment options was noncompliance in patients who they did not believe had the means to move forward with treatment. This illustrates a complex problem between the three groups (referring community physicians, transplant physicians, and the patients themselves) that this webinar series aims to address.

    Target Audience:

    This activity is intended for physicians, both referring physicians and transplant specialists, scientists, and other healthcare professionals who are part of the multidisciplinary team.

    Learning Objectives:

    Upon completion of this education activity, participants will be able to:

    1. Describe the long term psychosocial impacts in patients and their caregivers after transplant, and identify potential supports for long term survivorships.

    2. Define the general guidelines for post-transplant care in order to set expectations for patients in their recovery.

    3. Summarize trends in outcomes data, including rates of subsequent cancers after transplant.

    Accreditation Statement:

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and the American Society for Transplantation and Cellular Therapy. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.  

    Credit Designation 

    Physicians

    The France Foundation designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

    Method of Participation/How to Receive Credit:

    1. Review the activity objectives and CME/CE information.
    2. Participate in the CME/CE activity.
    3. Complete the CME/CE evaluation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
    4. If you are requesting educational credits or a certificate of participation, your certificate will be available for download.

    Disclosure Policy:

    In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and the American Society for Transplantation and Cellular Therapy (ASTCT) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and ASTCT resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and ASTCT seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ASTCT are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

    Activity Staff Disclosures:

    The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

    The planners, reviewers, editors, staff, CME committee, or other members at the American Society for Transplantation and Cellular Therapy who control content have no relevant financial relationships to disclose.

    Faculty Disclosures

    Faculty disclosures will be provided prior to the start of the activity.

    Commercial Supporter Disclosures

    No commercial support is provided for this webinar.

    Disclosure of Unlabeled Use:

    TFF and ASTCT require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ASTCT do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

    Disclaimer:

    The France Foundation and the American Society for Transplantation and Cellular Therapy present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the American Society for Transplantation and Cellular Therapy assume no liability for the information herein.

  • Contains 4 Product(s)

    This educational offering will focus on core topics in hematopoietic cell transplantation (HCT) and cellular therapy. The target audience is PGY2 Oncology Pharmacy Residents, but participation is open to all pharmacists or pharmacy trainees practicing or interested in transplantation and cellular therapy.

    This educational offering will focus on core topics in hematopoietic cell transplantation (HCT) and cellular therapy. The target audience is PGY2 Oncology Pharmacy Residents, but participation is open to all pharmacists or pharmacy trainees practicing or interested in transplantation and cellular therapy.  

    Topics:

    - Graft-versus-Host Disease (GVHD) – Presented by Zahra Mahmoudjafari, PharmD, BCOP, DPLA and Rebecca Gonzalez, PharmD, BCOP
    - Infection Prophylaxis in HCT – Presented by Arpita Shah Gandhi, PharmD, BCOP and Dennis Marjoncu, PharmD, BCOP
    - Chimeric Antigen Receptor (CAR) T-cell Therapies – Presented by Katie S. Gatwood, PharmD, BCOP and May T. Aziz, PharmD, BCOP
    - Conditioning Regimens Used in Hematopoietic Cell Transplantation – Presented by Binni Kunvarjee, PharmD, BCOP, Maggie Nelson, PharmD, BCOP, and Vinita Pai, PharmD, MS  

    Each module includes a recorded presentation, a post-test, a brief evaluation, and a certificate of completion.

  • Contains 4 Component(s), Includes Credits

    Join us on September 20 at 1 PM CT, for the third webinar in the new ASTCT & NMDP Sickle Cell Webinar Series, in honor of Sickle Cell Awareness month. This webinar will feature presentations from clinicians and patient speakers on challenges to finding stem cell sources and other barriers that both physicians and patients face throughout the process.

    Join us on September 20 at 1 PM CT, for the third webinar in the new ASTCT & NMDP Sickle Cell Webinar Series, in honor of Sickle Cell Awareness month. This webinar will feature presentations from clinicians and patient speakers on challenges to finding stem cell sources and other barriers that both physicians and patients face throughout the process. Other topics include:

    - Socioeconomic Barriers
    - Physicians attitude and practice
    - NMDP's Sickle Cell Warriors Program
    - Information about clinical trials

    This webinar will be moderated by Anna DeSalvo, a Senior Clinical Trials Patient Navigator with the NMDP Sickle Cell Warriors Program, and feature presentations by Dr. Lakshmanan Krishnamurti of Emory University. Each webinar in this series will also highlight patient's lived experiences within each of the topics.

    There will be a short Q&A section at the end of the webinar, so be sure to register and submit any questions in advance that you would like answered during the webinar by emailing info@astct.org. This webinar will be recorded and the recording and slides will be posted 24-48 hours after the live event.

    Accreditation Statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and the American Society for Transplantation and Cellular Therapy (ASTCT). The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.

    Continuing Medical Education Information

    This activity is jointly provided by The France Foundation and the American Society for Transplantation and Cellular Therapy.                

    Statement of Need:

    The Sickle Cell Warriors Program at NMDP is a patient services program that assists in typing for patients, financial assistance, counseling, patient education and providing peer connections. The primary feedback from patients in the Sickle Cell Warrior Program is that #1 barrier to treatment is physicians. Patients report that they are not being told about all of their treatment options; regardless of disease severity, they should at least be made aware of various options, but often they are not. Many patients go to the Sickle Cell Warriors Program to enroll in a clinical trial for transplant, but this usually does not cover cost of HLA typing. In this case, the referring physician has not gone through the process of HLA typing, either because of misinformation or because the physician refuses to provide an order for typing simply because they don’t agree with patients physicians. This is a clear miscommunication between the community oncologists and transplant physicians. In surveys, transplant physicians identify a lack of awareness, lack of confidence, and reliance on outdated data from the referring physicians. These referring physicians in a similar survey reported that their primary reason for not communicating all treatment options was noncompliance in patients who they did not believe had the means to move forward with treatment. This illustrates a complex problem between the three groups (referring community physicians, transplant physicians, and the patients themselves) that this webinar series aims to address.

    Target Audience:

    This activity is intended for physicians, both referring physicians and transplant specialists, scientists, and other healthcare professionals who are part of the multidisciplinary team.

    Learning Objectives:

    Upon completion of this education activity, participants will be able to:

    1. Review potential challenges in finding an appropriate stem cell source, and enrolling in clinical trials.

    2. Identify potential socioeconomic barriers for patients in the transplant process, and relevant supports and programs to alleviate potential barriers and burdens.

    3. Examine any underlying hesitancy in colleagues in the field, to help engage colleagues in a meaningful way throughout the transplant process.

    Accreditation Statement:

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and the American Society for Transplantation and Cellular Therapy. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.  

    Credit Designation 

    Physicians

    The France Foundation designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

    Method of Participation/How to Receive Credit:

    1. Review the activity objectives and CME/CE information.
    2. Participate in the CME/CE activity.
    3. Complete the CME/CE evaluation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
    4. If you are requesting educational credits or a certificate of participation, your certificate will be available for download.

    Disclosure Policy:

    In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and the American Society for Transplantation and Cellular Therapy (ASTCT) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and ASTCT resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and ASTCT seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ASTCT are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

    Activity Staff Disclosures:

    The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

    The planners, reviewers, editors, staff, CME committee, or other members at the American Society for Transplantation and Cellular Therapy who control content have no relevant financial relationships to disclose.

    Faculty Disclosures

    Faculty disclosures will be provided prior to the start of the activity.

    Commercial Supporter Disclosures

    No commercial support is provided for this webinar.

    Disclosure of Unlabeled Use:

    TFF and ASTCT require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ASTCT do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

    Disclaimer:

    The France Foundation and the American Society for Transplantation and Cellular Therapy present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the American Society for Transplantation and Cellular Therapy assume no liability for the information herein.

  • Contains 5 Component(s)

    This module will focus on Chimeric Antigen Receptor (CAR) T-cell Therapies.

    This module will summarize the mechanism of action and manufacturing process of CAR T-cells, evaluate data supporting the use of the FDA-approved CART T-cell products, and discuss the presentation and management of CAR T-cell toxicities. 

    Presented by:

    Katie S. Gatwood, PharmD, BCOP – Vanderbilt University Medical Center

    May T. Aziz, PharmD, BCOP – Virginia Commonwealth University Health System


  • Contains 2 Component(s)

    Join ASTCT Director of Government Relations, Alycia Maloney, JD and Reimbursement and Policy Advisors to ASTCT from Nimitt Consulting, Jugna Shah and Amy Rinkle, for the FY 2022 IPPS Final Rule webinar on September 16 at 11 a.m. CDT. The webinar will review FY 2022 IPPS final rule changes for CAR-T and allogeneic stem cell transplant, including financial and operational implications for providers.

    Join ASTCT Director of Government Relations, Alycia Maloney, JD and Reimbursement and Policy Advisors to ASTCT from Nimitt Consulting, Jugna Shah and Amy Rinkle, for the FY 2022 IPPS Final Rule webinar on September 16 at 11 a.m. CDT.

    Maloney, Shah, and Rinkle will cover:

    Government Relations (GR) and CMS Updates

    CAR-T, and other Cell Therapy Reimbursement Changes:
    - Use of FY 2019 data for FY 2022 rate-setting
    - Final payment policies for MS-DRG 018 for CAR-T
    - Change in MS-DRG naming and mapping of new therapies into MS-DRG 018
    - NTAP approvals for products in MS-DRG 018
    - Understanding CMS’ payment logic and reporting requirements for CAR-T clinical trial cases and expanded access cases CAR-T related ICD-10 coding updates
    - Understanding financial impact today and looking at reimbursement in the future

    Stem Cell Transplant (SCT) Reimbursement Changes:
    - Overall payment updates for autologous and allogeneic SCT
    - Final rule and Section 108 implications for MS-DRG 014
    - Operational requirements to receive cost reimbursement for all donor search and cell acquisition costs and expected financial impact
    - Other key updates

    There will be a short Q&A section at the end of the webinar, so be sure to register and submit any questions in advance that you would like answered during the webinar. If you are unable to join, the recording will be made available. Please consider sharing this webinar with your network of doctors, administrators, providers, or any other colleagues that may be interested.